Swaroop Vakkalanka

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

Howard A. Burris, Ian W. Flinn, Manish R. Patel et al. · The Lancet Oncology · 2018 · 205 citations

Medicine, Oncology, Pharmacology +16

Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530

Silvia L. Locatelli, Giuseppa Careddu, Simone Serio et al. · Clinical Cancer Research · 2018 · 78 citations

Medicine, Oncology, Pharmacology +14

Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Auris Huen, Bradley M. Haverkos, Jasmine M. Zain et al. · Cancers · 2020 · 63 citations · Full text

Pharmacy, Oncology, Pharmacokinetics +15

Design, Synthesis, and Identification of Silicon Incorporated Oxazolidinone Antibiotics with Improved Brain Exposure

B. Seetharamsingh, Remya Ramesh, Santoshkumar S. Dange et al. · ACS Medicinal Chemistry Letters · 2015 · 54 citations

Pharmacy, Medicinal Chemistry, Pharmacology +16

TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma

Owen A. O’Connor, Ian W. Flinn, Manish R. Patel et al. · Blood · 2015 · 28 citations

Medicine, Pharmacology, Pharmacotherapy +8